Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Int J Chron Obstruct Pulmon Dis. 2009;4:157-67. doi: 10.2147/copd.s3106. Epub 2009 Apr 15.
COPD is a complex disease with multiple pathological components, which we unfortunately tend to ignore when spirometry is used as the only method to evaluate the disorder. Additional measures are needed to allow a more complete and clinically relevant assessment of COPD. The earliest potential risk factors of disease in COPD are variations in the genetic background. Genetic variations are present from conception and can determine lifelong changes in enzyme activities and protein concentrations. In contrast, measurements in blood, sputum, exhaled breath, broncho-alveolar lavage, and lung biopsies may vary substantially over time. This review explores potential markers of early disease and prognosis in COPD by examining genetic markers in the alpha(1)-antitrypsin, cystic fibrosis transmembrane conductance regulator (CFTR), and MBL-2 genes, and by examining the biochemical markers fibrinogen and C-reactive protein (CRP), which correlate with degree of pulmonary inflammation during stable conditions of COPD. Chronic lung inflammation appears to contribute to the pathogenesis of COPD, and markers of this process have promising predictive value in COPD. To implement markers for COPD in clinical practice, besides those already established for the alpha(1)-antitrypsin gene, further research and validation studies are needed.
COPD 是一种复杂的疾病,具有多种病理成分,而当我们仅使用肺量测定法作为评估该疾病的唯一方法时,往往会忽略这些成分。需要额外的措施来实现对 COPD 的更全面和更具临床相关性的评估。COPD 疾病最早的潜在风险因素是遗传背景的差异。遗传变异从受孕时就存在,并能决定酶活性和蛋白浓度的终身变化。相比之下,血液、痰液、呼出气、支气管肺泡灌洗和肺活检中的测量值在时间上可能会有很大的变化。这篇综述通过检查α(1)-抗胰蛋白酶、囊性纤维化跨膜电导调节因子(CFTR)和甘露聚糖结合凝集素-2(MBL-2)基因中的遗传标记物,以及检查与 COPD 稳定期肺部炎症程度相关的生化标志物纤维蛋白原和 C 反应蛋白(CRP),探讨了 COPD 早期疾病和预后的潜在标志物。慢性肺炎症似乎对 COPD 的发病机制有贡献,而该过程的标志物在 COPD 中具有有前途的预测价值。为了在临床实践中实施 COPD 的标志物,除了已经确立的α(1)-抗胰蛋白酶基因标志物外,还需要进一步的研究和验证研究。